TICKERNERD
Menu
SIBNSIBNHealthcare · Medical Devices

SIBN Stock Forecast: SI-BONE, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$19
−1.26% on the day

The 9 Wall Street analysts covering SI-BONE, Inc. hold a median 12-month price target of $25 — +32.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 8 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$845.3M
Ticker Nerd rank
73 / 100
Median analyst target
$25
Analysts covering
9
Revenue$56.0M+15.2% y/y
Operating income−$4.8M
Net income−$4.1M
Free cash flow−$768K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
+1.3%
YTD
−4.4%
1Y
+24.0%
From 52W high
−11.9%
From 52W low
+62.4%
$12
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SIBN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SI-BONE, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
82
Quality
80
Volatility
66
Accruals
62
Growth
62
Momentum
59
Value
53
Size
46
Issuance
28

Revisions (82): Analysts have, on balance, been raising their forecasts.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SIBN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SIBN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26SIBNHigh $32Median $25Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $20Median $25High $32

The green dot is the last close — the median target sits +32.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 Aug 2026TD CowenMaintainsBuy$18 → $20
4 Aug 2026Truist SecuritiesReiteratesBuy$21 → $23
4 Aug 2026UBSMaintainsBuy$24 → $25
28 July 2026UBSInitiatesBuy$24
16 July 2026Truist SecuritiesMaintainsBuy—
16 July 2026Truist SecuritiesMaintainsBuy$18 → $21
12 May 2026TD CowenMaintainsBuy$22 → $18
12 May 2026TD CowenMaintainsBuy—
12 May 2026Truist SecuritiesReiteratesBuy$20 → $18
12 May 2026Truist SecuritiesReiteratesBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
24 Feb 2026TD CowenMaintainsBuy—
24 Feb 2026Truist SecuritiesReiteratesBuy—
27 Jan 2026TD CowenInitiatesBuy—
18 Dec 2025Truist SecuritiesMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
16 Dec 2025NeedhamMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsOverweight—
15 Oct 2025Truist SecuritiesMaintainsBuy—
5 Aug 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SIBN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SIBN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, SI-BONE, Inc. returned +24.0% against +16.2% for the S&P 500, dividends included.

SIBN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26SIBNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SIBN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

SI-BONE, Inc. (SIBN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−42.8×

Cheaper than 98% of US stocks

Price / sales
4.0×

Cheaper than 31% of US stocks

Price / book
4.6×

Cheaper than 21% of US stocks

EV / EBITDA
−65.5×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
15.2%

Higher than 63% of US stocks

Earnings growth (YoY)
15.2%

Higher than 53% of US stocks

Gross margin
79.5%

Higher than 90% of US stocks

Operating margin
−8.6%

Higher than 25% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−8.3%

Higher than 37% of US stocks

Return on assets
−4.6%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SI-BONE, Inc. (SIBN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SI-BONE, Inc. has a market value of $845.3M and an enterprise value of $742.1M.

  • Revenue in the twelve months to 30 June 2026: $213.6M. The latest quarter grew 15.2% year on year.

  • Net income over the same four quarters: −$14.6M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$4.4M.

  • Shares outstanding: 44.7M.

  • Trailing P/E: −42.8×; forward P/E: −57.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SI-BONE, Inc. employs 376 people — $568K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

SIBN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SIBNSI-BONE, Inc.$845.3M
73
AHCOAdaptHealth Corp.$824.3M
44
QDELQuidelOrtho Corp.$846.3M
33
INMDInMode Ltd.$809.3M
75
CBLLCeribell, Inc.$858.8M
38
VREXVarex Imaging Corp.$774.3M
83
BBNXBeta Bionics, Inc.$917.5M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SI-BONE, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SIBN news & analysis

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

GlobeNewsWire · 28 Sept 2026positive

SI-BONE announced it received FDA 510(k) clearance for its iFuse Granite Onyx implant, extending its compromised bone franchise beyond the pelvis. The platform, which received FDA Breakthrough Device Designation, is engineered for durable fixation in low-density bone.

Why it matters — FDA clearance expands SI-BONE's addressable product portfolio into new anatomical areas beyond its established pelvic franchise.

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

GlobeNewsWire · 31 Aug 2026neutral

SI-BONE, Inc. announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, where management will host a fireside chat on September 14, 2026, at 8:30 a.m. Pacific Time.

Why it matters — The upcoming fireside chat gives investors an opportunity to hear SI-BONE management discuss the company directly at a major healthcare investment conference.

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research · 25 Aug 2026positive

Zacks Investment Research published a piece examining whether Si-Bone (SIBN) has what it takes to be a top stock pick for momentum investors. The article evaluates the company's standing as a momentum stock.

Why it matters — A positive momentum assessment from Zacks could shape how investors perceive SIBN's near-term investment appeal.

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Zacks Investment Research · 24 Aug 2026positive

Zacks reports that the mean of analysts' price targets for Si-Bone (SIBN) points to roughly 25.3% upside in the stock. It notes this metric has not proven highly effective, but strong agreement among analysts raising earnings estimates indicates an upside.

Why it matters — A SIBN watcher would care because these analyst price targets and upward revisions to earnings estimates point to a potential upside in the stock.

FAQ

Frequently asked questions about SIBN stock

What is the SIBN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering SI-BONE, Inc. have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SIBN stock a buy right now?

Of the 9 analysts covering SI-BONE, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SI-BONE, Inc. 73 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SIBN?

As at 8 Oct 2026, SI-BONE, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (82 of 100).

Will SIBN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +32.6% from the last close, and Ticker Nerd's factor model ranks SI-BONE, Inc. 73 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SIBN stock forecast for 2030?

No analyst covering SI-BONE, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SIBN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has SIBN stock performed over the past year?

SI-BONE, Inc. returned +24.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SI-BONE, Inc. do?

SI-BONE, Inc. is a medical device company focused on developing procedural solutions for musculoskeletal disorders of the sacropelvic anatomy.

What is the latest news on SIBN?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis". SI-BONE announced it received FDA 510(k) clearance for its iFuse Granite Onyx implant, extending its compromised bone franchise beyond the pelvis. The platform, which received FDA Breakthrough Device Designation, is engineered for durable fixation in low-density bone.

Company

About SI-BONE, Inc.

SI-BONE, Inc. is a medical device company focused on developing procedural solutions for musculoskeletal disorders of the sacropelvic anatomy. SI-BONE’s product portfolio centers on minimally invasive implant systems designed for sacroiliac joint fusion, pelvic fixation, and related orthopedic applications. Its offerings include patented titanium implants, surgical instruments, and implantable bone products used in procedures addressing sacroiliac joint dysfunction, pelvic trauma, and spinopelvic reconstruction. The company serves physicians and hospitals in the United States and selected international markets, supporting treatment workflows through direct sales and third-party distribution channels. Based in Santa Clara, California, SI-BONE plays a specialized role in the orthopedics and spine market by providing anatomy-specific technologies for patients with complex bone and joint conditions.

CEO Ms. Laura A. Francis MBA · 376 employees · United States · https://si-bone.com